Lipo-Hydroxamic Acid Derivative for Topical Corneal Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Lipoic acid's acidic structure limits its bioavailability and distribution to corneal tissue, leading to low efficacy in treating corneal dystrophy, and systemic administration causes adverse effects.
Innovation Solution
Development of lipo-hydroxamic acid derivatives for topical ocular use, including compounds represented by Chemical Formulas 1 and 2, which are converted into lipoic acid for enhanced absorption and reduce mucosal irritation, providing antioxidant, anti-inflammatory, and cytoprotective effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lipoic acid is administered orally to treat corneal dystrophy, then it provides antioxidant activity, but its acidic structure results in low bioavailability and poor distribution to corneal tissue
Solution Approach 1:
The patent modifies the chemical structure of lipoic acid by replacing the carboxylic acid group with a lipo-hydroxamic acid derivative structure. This parameter change in molecular structure eliminates the acidic properties that caused poor absorption while maintaining the antioxidant activity, thereby improving bioavailability and tissue distribution to the cornea
Solution Approach 2:
The lipo-hydroxamic acid derivative acts as a structural intermediary that preserves the beneficial antioxidant properties of lipoic acid while removing the harmful acidic characteristics. This intermediary structure enables effective delivery to corneal tissue without the absorption limitations of the original compound
2Reliability
If lipoic acid is administered via mucosal routes to treat corneal dystrophy, then it may reach the target tissue, but it causes adverse effects including irritation and localized sensation of heat
Solution Approach 1:
The patent changes the chemical parameter of the lipoic acid molecule by converting the carboxylic acid functional group into a lipo-hydroxamic acid derivative. This modification removes the acidic properties responsible for mucosal irritation and heat sensation, allowing safe administration while maintaining therapeutic efficacy in treating corneal dystrophy
3Ease of operation
If topical eye drop treatment is used for corneal dystrophy, then it may improve drug delivery to the cornea, but the acidic structure of lipoic acid still limits its absorption and distribution
Solution Approach 1:
The patent modifies the molecular parameters of lipoic acid by introducing a lipo-hydroxamic acid derivative structure that eliminates acidic properties. This structural change enables effective absorption and distribution through topical eye drop administration, overcoming the absorption limitations imposed by the original acidic structure while maintaining the route of administration advantage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipo-hydroxamic acid derivatives inhibit oxidative stress and apoptosis in corneal endothelial cells, effectively treating or preventing ocular diseases like corneal dystrophy while avoiding systemic side effects.
Implementation Method 1
Lipoic acid primarily functions as a coenzyme involved in oxidation-reduction reactions, thereby exhibiting antioxidant activity within the body
Implementation Method 2
lipo-hydroxamic acid derivatives for topical ocular use, including compounds represented by Chemical Formulas 1 and 2, which are converted into lipoic acid for enhanced absorption
Data Source
Figure 1~3
Figure 4~5
Figure 6~7
AI summary
The present invention relates to a lipo-hydroxamic acid derivative and a pharmaceutical use thereof. The derivative exhibits excellent stability in ophthalmic formulation, and has been demonstrated to inhibit apoptosis and oxidative stress induced under corneal dystrophy-mimicking conditions in corneal endothelial cells, as well as to regulate the expression of factors associated with fibrosis and cellular degeneration, thereby being usefully applicable as a composition for the prevention, treatment, or amelioration of eye diseases.